SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma
Top Cited Papers
Open Access
- 30 November 2014
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 135 (11), 2711-2720
- https://doi.org/10.1002/ijc.28913
Abstract
Cyclophosphamide-dacarbazine-vincristine regimen is recommended for the treatment of malignant pheochromocytoma and paraganglioma (MPP); however, dacarbazine is the only recognized active drug in neuroendocrine tumours. We investigated the therapeutic benefit of temozolomide (TMZ), an oral alternative to dacarbazine, in patients with MPP. This is a retrospective study of consecutive patients with documented progressive MPP. We examined the correlation between Succinate dehydrogenase B (SDHB) mutation and O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation and MGMT expression in the French nation-wide independent cohort of 190 pheochromocytomas or paragangliomas (PP). Progression-free survival (PFS) according to RECIST 1.1 and PERCIST 1.0 criteria was the primary end point. Fifteen consecutive patients with MPP were enrolled; ten (67%) carried a mutation in SDHB. The mean dose intensity of TMZ was 172 mg/m(2)/d for 5 days every 28 days. Median PFS was 13.3 months after a median follow-up of 35 months. There were five partial responses (33%), seven stable (47%) and three progressive diseases (20%). Grade 3 toxicities were lymphopenia in two patients and hypertension in one. Partial responses were observed only in patients with mutation in SDHB. MGMT immunohistochemistry was negative in tumour samples from four patients who responded to treatment. SDHB germline mutation was associated with hypermethylation of the MGMT promoter and low expression of MGMT in 190 samples of the French nation-wide independent cohort. This study demonstrates that TMZ is an effective antitumour agent in patients with SDHB-related MPP. The silencing of MGMT expression as a consequence of MGMT promoter hypermethylation in SDHB-mutated tumours may explain this finding.Keywords
Funding Information
- Programme Hospitalier de Recherche Clinique grant COMETE 3 (AOM 06 179)
- Agence Nationale de la Recherche (ANR 11 JSV1 007 01 MODEOMAPP)
This publication has 34 references indexed in Scilit:
- One-Year Progression-Free Survival of Therapy-Naive Patients With Malignant Pheochromocytoma and ParagangliomaJournal of Clinical Endocrinology & Metabolism, 2013
- Bone Metastases and Skeletal-Related Events in Patients With Malignant Pheochromocytoma and Sympathetic ParagangliomaJournal of Clinical Endocrinology & Metabolism, 2013
- Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals Of Oncology, 2012
- An Update on the Genetics of Paraganglioma, Pheochromocytoma, and Associated Hereditary SyndromesHormone and Metabolic Research, 2012
- Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra‐adrenal paragangliomasCancer, 2011
- Predictive Factors for Malignant Pheochromocytoma: Analysis of 136 PatientsJournal of Urology, 2011
- Clinical Risk Factors for Malignancy and Overall Survival in Patients with Pheochromocytomas and Sympathetic Paragangliomas: Primary Tumor Size and Primary Tumor Location as Prognostic IndicatorsJournal of Clinical Endocrinology & Metabolism, 2011
- Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazineCancer, 2008
- Succinate Dehydrogenase B Gene Mutations Predict Survival in Patients with Malignant Pheochromocytomas or ParagangliomasJournal of Clinical Endocrinology & Metabolism, 2007
- Malignant Pheochromocytoma: Effective Treatment with a Combination of Cyclophosphamide, Vincristine, and DacarbazineAnnals of Internal Medicine, 1988